secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0001493152-23-037533
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte expands NKI/Oncode collaboration to study LB-100 + immunotherapy in additional cancers
--------------------------------------------------------------------------------

- Amendment 2 extends the Development Collaboration Agreement for two more years.
- New focus: drug synergies of LB-100 with immunotherapy plus synthetic lethal combinations in more cancer types.
- Prior two-year collaboration successfully identified LB-100 combinations for colon cancer.
- Parties include Netherlands Cancer Institute and Oncode Institute, with Prof. René Bernards on Lixte's board.
- No financial terms or milestones disclosed in the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/0001493152-23-037533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-037533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer